ArticlePain2026
Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study.
Article in Pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPain is a major concern in patients with advanced pancreatic cancer, significantly affecting quality of life, treatment tolerance, and end-of-life experience. However, data on its prevalence, course, and determinants remain limited, particularly regarding the dynamics of pain as a primary outcome in real-world patient populations. This nationwide cohort study, conducted within the PACAP-PROM registry (2016-2023), included patients with locally advanced (LAPC) or metastatic pancreatic cancer (mPC). Pain was assessed using 5 items from the EORTC QLQ-C30, PAN26, and EQ-5D-5L questionnaires, with the primary outcome being pain prevalence at baseline and comparisons between LAPC and mPC. Secondary outcomes included pain trajectories over 3 to 18 months and the association between chemotherapy and pain, evaluated using mixed-effects logistic regression. Overall, 794 patients were included, of whom 648 (82%) received cancer therapy, and 146 (18%) received best supportive care (BSC). At baseline, 54% to 78% of patients reported pain, with no differences between LAPC and mPC. Although pain prevalence decreased at 3 months, variable patterns developed thereafter. Patients receiving BSC reported more pain (57% vs 38%, P = 0.029) and greater pain-related interference with daily activities (53% vs 38%, P = 0.024). Chemotherapy was independently associated with lower odds of higher pain severity categories for current pain (OR 0.51; 95% CI 0.37-0.70) and pain interference (OR 0.44; 95% CI 0.31-0.63). In conclusion, pain prevalence exceeds 50% in patients with advanced pancreatic cancer and remains a key concern that can be positively influenced by chemotherapy. These findings emphasize the need for routine pain assessment and individualized symptom management from diagnosis onward.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.